Published in Blood Weekly, April 12th, 2001
Ariela Noy and colleagues at the Memorial Sloan-Kettering Cancer Center investigated the power and accuracy of a clonotypic polymerase chain reaction (cPCR) assay using oligonucleotides specific to each patient's tumor cells.
Noy et al. found that their screen was both sensitive and specific for finding minimal residual disease (MRD), perhaps even more so than conventional assays.
All 10 patients in either partial remission or nodular partial...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.